NRIX 8-K
Nurix Therapeutics, Inc. (NRIX)
8-K
2026-01-12
For: 2026-01-12
View Original
Added on
April 11, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K
___________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 12, 2026
___________________________________________
(Exact Name of Registrant as Specified in its Charter)
___________________________________________
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
(415 ) 660-5320
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
1700 Owens Street, Suite 205, San Francisco, California
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
As previously announced, on January 12, 2026, Nurix Therapeutics, Inc. (the “Company”) will present an overview of the Company’s performance in 2025 and its major goals for 2026 at the 44th Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s presentation materials for the JPM Conference is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Also on January 12, 2026, the Company issued the press release attached as Exhibit 99.2 hereto, which is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following exhibits are filed herewith and this list is intended to constitute the exhibit index:
| Exhibit No. | Exhibit Title or Description | |||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NURIX THERAPEUTICS, INC. | ||||||||
Date: January 12, 2026 | By: | /s/ Christine Ring | ||||||
| Christine Ring, Ph.D., J.D. | ||||||||
| Chief Legal Officer | ||||||||
3
Protein Degraders to Outmatch Cancer and Autoimmune Disease J.P. Morgan Healthcare Conference January 12, 2026 Exhibit 99.1
Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix Therapeutics, Inc. (“Nurix”, the “Company,” “we,” “us” or “our”), may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the therapeutic potential of Nurix's drug candidates; Nurix's plans for the clinical development of its drug candidates; the planned timing for the initiation and enrollment of patients in current and future clinical trials of Nurix's drug candidates; the planned timing for the provision of updates and findings from Nurix's clinical trials; our future financial or business plans; our future performance, prospects and strategies; future conditions, trends, and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of the clinical trial programs for our drug candidates; the potential benefits of our collaborations, including potential milestone and sales- related payments; the potential advantages of DEL-AI and our drug candidates; the extent to which our scientific approach, our drug discovery engine, targeted protein degradation and degrader antibody conjugates may potentially address a broad range of diseases; the extent animal model data, in vitro potency data, and proteomics data predicts human efficacy; the timing and success of the development and commercialization of our current and anticipated drug candidates; and our ability to fund our operations into 2028. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix will be able to advance, obtain regulatory approval of and ultimately commercialize its current and prospective drug candidates, including bexobrutideg, zelebrudomide or NX-1607; (ii) risks and uncertainties inherent in the drug discovery and drug development process; (iii) the timing and results of clinical trials; (iv) Nurix’s ability to fund development activities and achieve development goals; (v) risks and uncertainties relating to Nurix's collaboration partners, including the speed of development of partnered programs and the timing and receipt of payments from Nurix's collaboration partners, including milestone payments and royalties on future potential product sales; (vi) the impact of macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, instability in the global banking system, uncertainty with respect to the federal budget and debt ceiling, war, military or regional conflicts, and global health pandemics, on Nurix’s clinical trials and operations; (vii) Nurix’s ability to protect intellectual property and (viii) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2025, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this presentation speak only as of the date of this presentation, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Furthermore, while we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source. 2
3 OUR MISSION To establish degrader-based medicines at the forefront of patient care
Targeted protein degradation (TPD) Leading the Next Frontier in Drug Development 4 Evolution of new therapeutic modalities AntibodiesSmall molecule inhibitors Nucleic acid-based therapies (Antisense, RNAi Gene Therapy, CRISPR) Targeted protein degraders
2025: A Breakthrough Year Achieving Several Key Milestones 5 Clinical Execution Excellence Initiated pivotal DAYBreak-201 Phase 2 study designed to support Accelerated Approval of bexobrutideg in relapsed/refractory CLL Robust results presented at ASH: 83% ORR and 22.1-month median PFS Secured 600 mg dose per Project Optimus Pipeline and Partnership Momentum Strengthened Financial Position IRAK4 degrader in ongoing Phase 1 SAD/MAD study with partner Gilead STAT6 degrader advanced to IND-enabling studies with partner Sanofi Initiated healthy volunteer studies with new bexobrutideg formulation for I&I Strengthened balance sheet with $250M follow-on offering $47M earned in non-dilutive capital through discovery partnerships Well capitalized with pro forma cash/investments of $663.8 million* *Cash balance as of August 31, 2025, plus the net proceeds from the October 2025 registered direct offering
Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs in Oncology and Inflammation & Immunology 6 Program Target Modality Therapeutic area Discovery IND-Enabling Phase 1A Phase 1B/2 Pivotal Bexobrutideg (NX-5948) BTK Degrader B-cell malignancies Zelebrudomide (NX-2127) BTK-IKZF Degrader B-cell malignancies NX-1607 CBL-B Inhibitor of degradation Immuno-oncology BRAF degrader Pan-mutant BRAF Degrader Solid tumors Multiple Undisclosed Degrader Undisclosed Multiple Undisclosed Degrader Undisclosed Multiple Undisclosed DAC Undisclosed Program Target Modality Therapeutic area Discovery IND-Enabling Phase 1A Phase 1B Phase 2/3 Bexobrutideg (NX-5948) BTK Degrader Autoimmune cytopenia in CLL patients NX-0479 / GS-6791 IRAK4 Degrader Rheumatoid arthritis and other inflammatory diseases NX-3911 STAT6 Degrader Type 2 inflammatory diseases Undisclosed Undisclosed Degrader Inflammation / autoimmune Multiple Undisclosed DAC Inflammation / autoimmune O nc ol og y In fla m m at io n & Im m un ol og y
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 7 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action. Degradation removes all functions of BTK unlike BTK inhibitors Removes both BTK enzymatic activity and scaffolding functions
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 8 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action. Degradation removes all functions of BTK unlike BTK inhibitors One molecule of bexobrutideg degrades thousands of BTK proteins per hour
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 9 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action. Degradation removes all functions of BTK unlike BTK inhibitors BTK St at is tic al S ig ni fic an ce -l og 10 [P ] Protein Abundance Fold Change (log2) Global proteomics analysis shows bexdeg selectively degrades BTK with no off-target degradation
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 10 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action. Degradation removes all functions of BTK unlike BTK inhibitors Bexobrutideg shows superior mutational coverage compared to BTK inhibitors Most potent cell killing BTK-W T BTK-C 48 1S BTK-C 48 1R BTK-V 41 6L BTK-T47 4I BTK-L5 28 W Bexobrutideg Pirtobrutinib Vecabrutinib Fenebrutinib Ibrutinib Acalabrutinib Zanubrutinib GI-50 (nM) 0 1000 2000 3000 4000 5000
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 11 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action. Degradation removes all functions of BTK unlike BTK inhibitors Only BTK degrader to demonstrate clinical activity in patients with CNS disease including complete responses
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 12 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in difficult to treat B- cell malignancies Acts catalytically with unprecedented potency Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease BTK, Bruton's tyrosine kinase; CNS, central nervous system; MOA, mechanism of action; r/r CLL, relapsed or refractory chronic lymphocytic leukemia. Degradation removes all functions of BTK unlike BTK inhibitorsHigh objective response rate and prolonged PFS in r/r CLL patients Efficacy across all doses (50mg – 600mg) Phase 1a (n=47) Objective response rate (ORR) 83.0% Median progression-free survival (PFS) 22.1 months
Broad Clinical Activity Across Patients with BTK Mutations, High-Risk Molecular Features and/or CNS Involvement aWaterfall plot includes patients with measurable lymph node status (n=93); mutations were reported at VAF >5%; bPatients could have no mutations, a single mutation, or multiple mutations ATM, ataxia-telangiectasia mutated; BTK, Bruton’s tyrosine kinase; BTKi, BTK inhibitor; cBTKi, covalent BTKi; ncBTKi, non-covalent BTKi; CLL, chronic lymphocytic leukemia; CNS, central nervous system; iwCLL, International Workshop on CLL; NOTCH1, neurologic locus notch homolog protein 1; PLCG2, phospholipase C gamma 2; SPD, sum of products diameters Dashed line indicates iwCLL response criteria threshold (50%) Data cutoff: 19 Sep 2025 CNS involvement at baseline * * *** R ed uc tio n in ly m ph n od e si ze % c ha ng e fro m b as el in e in S PD o f t ar ge t l es io n( s) Mutation status Unavailable Wild type Single mutant Multiple mutant Hi gh -r is k m ol ec ul ar fe at ur es B TK i r es is ta nc e m ut at io ns nc BT Ki cB TK i 13
Bexobrutideg Demonstrates Deep and Durable Responses in CLL Updated Phase 1a results presented at ASH 2025 14 Robust Response Rate in Patients with a Median of 4 Prior Lines of Therapy Long-term Disease Control with a Median PFS of 22.1 Months Across All Doses Tested (50mg – 600mg, n=48) CLL response-evaluable patientsa Response analysis (n=47) Objective response rate (ORR),b % (95% CI) 83.0 (69.2–92.4) Best response, n (%) Complete response (CR) 2 (4.3) Nodal partial response (nPR) 1 (2.1) Partial response (PR/PR-L) 36 (76.6) Stable disease (SD) 6 (12.8) Progressive disease (PD) 2 (4.3) Median duration of responsec, months (95% CI) 20.1 (12.2–NE) (n=39) aPatients who were treated with bexobrutideg having ≥1 post-baseline disease assessment or documented clinical PD. bObjective response rate was evaluated using iwCLL criteria and included CR + PR + PR-L. cKaplan-Meier estimate Ev en t-f re e ra te Month 0 No. at risk 48 40 36 27 17 10 3 0 16 1.0 0.2 0.4 0.6 0.8 1412108642 30282624222018 45 36 32 20 5 5 4 1 1 0 32 Censored+ Median PFS, months (95% CI) 22.1 (11.2–NE) Median PFS follow-up, months (95% CI) 16.6 (14.0–19.3) Data cutoff: 19 Sep 2025
Comparable AE profile for patients overall and at the 600 mg dose selected per Project Optimus Bexobrutideg is Well Tolerated in Patients with Relapsed/Refractory CLL Data cutoff: 19 Sep 2025aPurpura/contusion includes episodes of contusion or purpura; bAggregate of ‘neutrophil count decreased’ or ‘neutropenia’; cFatigue was transient; dAggregate of ‘thrombocytopenia’ and ‘platelet count decreased’; eAggregate of ‘rash’ and ‘rash maculopapular’ and ‘rash pustular’; fAggregate of ‘COVID-19’ and ‘COVID-19 pneumonia’ AE, adverse event; RP2D, recommended Phase 2 dose; TEAE, treatment-emergent adverse event • Tolerable safety profile • No dose-limiting toxicities • No systemic fungal infections or Grade 4 infections of any kind reported • Single event of new onset atrial fibrillation consistent with the rate in the age-matched general population • Three Grade 5 AEs (all deemed not related to bexobrutideg) TEAEs (all doses, n=126) TEAEs (600 mg dose, n=70) Patients, % -100 -80 -60 -40 -20 0 20 40 60 80 100 COVID-19 Sinusitis Back pain Arthralgia Nausea Upper respiratory tract infection Peripheral edema Cough Rash Headache Thrombocytopenia Anemia Diarrhea Fatigue Petechiae Neutropenia Purpura/contusion 4080 Grade 1/2 Grade ≥3 Purpura/contusiona eutropeniab t i Fatiguec i rr i Thro bocytopeniad ashe ri r l r r ir t r tr t i f ti rt r l i i i iti f 15
Preliminary efficacy in Phase 1b randomized cohort of 200 mg vs 600 mg Higher ORR and PFS Observed at 600 mg Dose Selected for Pivotal Trials Data cutoff: 19 Sep 2025aObjective response rate includes CR + nPR + PR + PR-L CI, confidence interval; ORR, objective response rate; PFS, progression-free survival Response- evaluable patients 200 mg (n=19) 600 mg (n=18) Objective response rate,a % (95% CI) 73.7 (48.8–90.9) 83.3 (58.6–96.4) Ev en t-f re e ra te Month 0 0 No. at risk 0.2 0.4 0.6 0.8 1.0 2 4 6 8 10 19 20 17 18 16 17 12 11 11 9 5 1 600 mg 200 mg 12 0 0 Censored 600 mg 200 mg + 16
Latest Bexobrutideg Data Supports a Best-in-Class Pivotal Trial Strategy 17 Endpoint Bexobrutideg Pirtobrutinib (FDA full approval 12/3/2025) Objective Response Rate (ORR) 83.0% 65% (69% investigator) Median Duration of Response (DOR) 20.1 months 13.8 months (13.9 investigator) Median Progression-Free Survival (PFS) 22.1 months 14.0 months Study NX-5948-301 (Phase 1a) BRUIN-321 (vs BR/IR) Bexobrutideg was evaluated in a more heavily pretreated population than pirtobrutinib: • Median prior lines of therapy: 4 vs 3 • ≥4 prior lines of therapy: 56% vs 33% • Prior non-covalent BTK inhibitor exposure: 27% vs 0% • Prior BCL-2 inhibitor exposure: 83% vs 50% Source: NX-5948-301 study data cut off Sept 19, 2025, and Sharman et al, JCO 43: 2538-2549, June 2025 CLL, chronic lymphocytic leukemia; BTK, Bruton’s tyrosine kinase; BCL-2i, BCL-2 inhibitor
DAYBreak Pivotal Phase 2 Single-Arm Study Designed to Support Bexobrutideg Accelerated Approval 18 600 mg cleared for pivotal studies in R/R CLLFirst patient dosed in October 2025 Key Eligibility • R/R CLL/SLL • Triple- exposed (post-cBTKi, ncBTKi & BCL-2i) Response assessment every 8 weeks until week 24, every 12 weeks after ORR per iwCLL as assessed by IRC Response assessment & survival follow-up Enrollment (N= ~100) TR IA L D ES IG N Single Arm: Bexobrutideg orally 600 mg QD Primary efficacy endpoint Safety follow- up r/r CLL, relapsed or refractory chronic lymphocytic leukemia; ORR, objective response rate; iwCLL, International Workshop on CLL; IRC, Independent Review Committee; QD, once daily; SLL, small lymphocytic lymphoma; cBTKi, covalent BTK inhibitor; ncBTKi, non-covalent BTK inhibitor; BCL-2i, BCL-2 inhibitor
TR IA L D ES IG N DAYBreak Phase 3 Confirmatory Trial Positions Bexobrutideg for Full Approval 19 Stratified by high-risk genetic features and prior lines of therapy Note: Final design pending regulatory feedback r/r CLL, relapsed or refractory chronic lymphocytic leukemia; PFS, progression-free survival; iwCLL, International Workshop on CLL; IRC, Independent Review Committee; QD, once daily; SLL, small lymphocytic lymphoma; cBTKi, covalent BTK inhibitor R 1:1 Primary efficacy endpoint Enrollment (N= ~600) Progression-free survival (PFS) per iwCLL as assessed by IRC (superiority) Response assessment & survival follow-up Arm A: Bexobrutideg 600 mg oral QD Key Eligibility • 2L+ R/R CLL/SLL • Prior cBTKi Arm B: Pirtobrutinib Safety follow-up Single trial strategy to support global approval and establish superiority of degrader mechanism of action Designed to evaluate superiority to latest approved BTKi, pirtobrutinib
NX-5948-203: Phase 1b/2 Combination Study to Address Emerging Treatment Standards in CLL 20 CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; ORR, objective response rate; QD, once daily; RP2D, recommended Phase 2 dose Strategy provides potential path to 1L CLLCombination regimen of bexobrutideg + BCL-2i maximizes 2L market share opportunity TR IA L D ES IG N Bexobrutideg + venetoclax Cohort 1: 2L+ CLL/SLL Bexobrutideg + venetoclax + rituximab Cohort 2: 2L+ CLL/SLL Bexobrutideg + venetoclax + obinutuzumab Cohort 3: 2L+ CLL/SLL Additional cohorts: Exploring additional combinations RP2D Primary efficacy endpoint ORR per iwCLL as assessed by IRC Safety follow-up Response assessment & survival follow-up RP2D Phase 1b: Safety run-in 450 mg QD & 600 mg QD N = minimum of 3 at low dose and 6 patients at high dose Phase 2: Cohort 1-3 expansion N = ~20 patients per cohort Bexobrutideg + venetoclax +/- obinutuzumab 1L+ CLL/SLL Cohort 4-5
Nurix Has a Clinical Development Plan Addressing Large Segments of the CLL Market as Both a Mono- and Combo- Therapy 21 ~19K treated in R/R CLL ~19K1L treated ~11K2L treated ~8K3L+ treated US Drug-Treated IncidenceDrug-Treated Incidence in Major Markets US, Canada, Europe, Japan, China ~60K treated in R/R CLL ~61K1L treated ~36K2L treated ~24K3L+ treated Current BTK inhibitor sales annualizing at $12.5 billion with approximately $9.5 billion in CLL Sources for US, EU4+UK, and Japan: [1] Clarivate / DRG Landscape and Forecast Research Report NHL and CLL, April 2023 For Canada, we assume similar drug treated incidence as US and adjust for the smaller Canadian population; For Europe, we adjust EU4+UK drug treated incidence for the total Europe population; For China, we assume lower drug treated incidence based on literature reference: https://ashpublications.org/ashclinicalnews/news/1473/Disease-Detectives-CLL-in-Asia
Unlocking Waves of Clinical Benefit and Value Creation 22 * Phase 2 single-arm study designed to support Accelerated Approval Pivotal DAYBreak CLL-201 trial initiated in October 2025; Confirmatory Phase 3 planned to start in 2026 Phase 1b/2 combination study planned to start in 2026 to enable pivotal studies Plans for indication expansion in oncology and inflammatory indications Bexobrutideg has the potential to create significant value through its broad application across BTK mediated diseases r/r CLL Accelerated Approval* 2L+ CLL Confirmatory Monotherapy 2L+ CLL Combination Potential 1L+ CLL Combination I&I Neuro, derm, heme WM / NHL
Nurix’s Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases 1Patient estimate across key indications in U.S., EU5 and JP (2023); 2Annual sales across modalities (2023) Sources: GlobalData, Lumanity analysis, Evaluate Pharma, IQVIA Institute for Human Data Science, Global Use of Medicines: Outlook to 2028, January 2024. Indication abbreviations defined in notes section in the back of the deck. 23 BTK Bexobrutideg opportunity (wholly owned) >6M patients1 Including CSU, HS, MS, wAIHA >$18B annual sales2 B-cell & myeloid cell-driven inflammation STAT6 Type 2 inflammation NX-3911 opportunity (partnered with Sanofi) >125M patients1 Including asthma, AD, BP, CSU, COPD, CRwNP, EoE, PN >$34B annual sales2 IRAK4 IL-1R/TLR-driven inflammation NX-0479/GS-6791 opportunity (partnered with Gilead) >110M patients1 Including asthma, AD, HS, PsO, PsA, RA, SLE, CLE, CD, UC >$100B annual sales2
Nurix’s Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases 24 BTK Bexobrutideg (wholly owned) New tablet formulation in Phase 1 SAD/MAD study B-cell & myeloid cell-driven inflammation STAT6 Type 2 inflammation NX-3911 (partnered with Sanofi) IND-enabling studies ongoing 50/50 U.S. profit share option IRAK4 IL-1R/TLR-driven inflammation NX-0479/GS-6791 (partnered with Gilead) Phase 1 SAD/MAD study ongoing 50/50 U.S. profit share option
2026: Building the Future of Protein Degradation 25 Enrollment of Pivotal Phase 2 trial – DAYBreak CLL-201 Initiation of bexobrutideg confirmatory Phase 3 study in r/r CLL – DAYBreak CLL-306 Initiation of bexobrutideg combination study in CLL Potential GS-6791 IRAK4 degrader Phase 1 results from Gilead* Potential NX-3911 STAT6 degrader IND filing by Sanofi* Bexobrutideg new tablet formulation SAD/MAD study supporting IND in I&I Bexobrutideg Phase 1a/b CLL cohorts Bexobrutideg Phase 1a/b NHL cohorts Zelebrudomide Phase 1a cohorts Execute Pivotal Development Pathway in CLL Advance Degrader Programs in I&I Clinical Data Updates * Nurix estimate for partnered programs using industry standard timelines based on current stage of development (not official guidance of partners).
26 Q&A
Abbreviations • AD = Atopic dermatitis • BP = Bullous pemphigoid • COPD = Chronic obstructive pulmonary disease • CD = Crohn’s disease • CRwNP = Chronic rhinosinusitis with nasal polyps • CSU = Chronic spontaneous urticaria • CLE = Cutaneous lupus erythematosus • EoE = Eosinophilic esophagitis • wAIHA = Warm autoimmune hemolytic anemia • HS = Hidradenitis suppurativa • MS = Multiple sclerosis • PsA = Psoriatic Arthritis • PN = Prurigo nodularis • RA = Rheumatoid arthritis • SLE = Systemic lupus erythematosus without Lupus Nephritis • UC = Ulcerative Colitis 27
[Nurix Logo]
Exhibit 99.2
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation
Advance a growing portfolio of partnered inflammation and immunology programs, including potent and selective degraders of IRAK4 and STAT6
Leverage DEL-AI platform to drive discovery against high-value targets across internal and partnered programs
BRISBANE, CA, January 12, 2026 -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today highlighted the Company’s achievements in 2025 and outlined key objectives and anticipated milestones for 2026, which will be the subject of Nurix’s corporate update at the 44th Annual J.P. Morgan Healthcare Conference today at 4:30 p.m. PT, in San Francisco.
“2025 was a defining year for Nurix, having advanced our potentially best-in-class BTK degrader, bexobrutideg, into pivotal development for patients with relapsed or refractory CLL,” said Arthur T. Sands, president and chief executive officer of Nurix. “As we enter 2026, we are focused on executing the DAYBreak CLL-201 study and initiating the confirmatory Phase 3 trial, DAYBreak CLL-306. We are also excited to advance our pipeline of wholly owned and partnered programs in inflammation and autoimmune diseases, including our new tablet formulation of bexobrutideg, our IRAK4 degrader program partnered with Gilead, and our STAT6 degrader program partnered with Sanofi. With our pivotal DAYBreak program underway, a strong balance sheet, and multiple catalysts across oncology and immunology, we believe Nurix is exceptionally well positioned to make 2026 a transformative year for the Company and the field of targeted protein degradation.”
2025 Select Accomplishments and Business Highlights
Potential Best-in-Class BTK degrader, Bexobrutideg, in CLL
•Presented new and updated clinical and preclinical data supporting a potential best-in-class BTK degrader profile. New and updated clinical data were presented in December 2025 at the 67th American Society of Hematology Annual Meeting (ASH2025) that provide a maturing clinical picture of bexobrutideg’s efficacy, durability, and tolerability. Highlights included an 83% objective response rate, including two complete responses (4.3%) in CLL patients with a median of four prior lines of treatment. Responses were durable and deepened over time with a median progression-free survival estimated at 22.1 months, which is highly competitive with currently approved agents in a similar line of therapy. Bexobrutideg was well
tolerated with no dose-limiting toxicities across all doses tested. New preclinical data were presented in October 2025 that support bexobrutideg’s potential best-in-class BTK degrader profile, demonstrating superior degradation potency, broad coverage of clinically relevant BTK mutations, and exquisite selectivity. These findings strengthen the Company’s conviction that bexobrutideg may prove to be a clinically superior medicine for the treatment of patients with CLL and other B-cell driven diseases.
•Successfully addressed FDA’s Project Optimus with the selection of the 600 mg once daily dose for pivotal development in r/r CLL. The selection of the 600 mg dose was supported by data from a randomized cohort within the Phase 1b study comparing 200 mg and 600 mg in accordance with Project Optimus and reflects alignment with global regulators, including the U.S. Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency, and the European Medicines Agency. The results, subsequently reported at ASH2025, demonstrated a trend toward a higher objective response rate and longer progression-free survival with the 600 mg dose without an increase in adverse events. The clearance by regulators of the 600 mg dose allows Nurix to optimize bexobrutideg’s therapeutic effect, providing patients the opportunity to regain control of CLL that has progressed or has failed to respond to other therapies.
•Initiated pivotal clinical development in patients with relapsed or refractory CLL. In October 2025, Nurix initiated enrollment in the DAYBreak CLL-201 pivotal Phase 2 study (NCT07221500). This single-arm, global study is evaluating bexobrutideg at 600 mg once daily in patients with relapsed or refractory CLL whose disease progressed following treatment with a BTK inhibitor and a BCL2 inhibitor. The trial is designed to support accelerated approval of bexobrutideg in triple-exposed CLL/SLL patients. Nurix plans to initiate a randomized confirmatory Phase 3 trial in 2026 to support full approval of bexobrutideg.
First-in-class CBL-B Inhibitor NX-1607
•Presented positive Phase 1a clinical data demonstrating immune activation and clinical activity. New Phase 1a clinical data for NX-1607 were presented at the European Society for Medical Oncology (ESMO) Congress in October and the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting in November, demonstrating dose-dependent pharmacologic activity and signals of clinical activity across a diverse set of 82 patients with eleven different tumor types. Clinical activity was observed through reductions in tumor-specific biomarkers such as prostate-specific antigen (PSA) in prostate cancer and carcinoembryonic antigen (CEA) in colorectal cancer. Notably, there was a confirmed partial response in a patient with micro-satellite stable colorectal cancer (MSS CRC), a tumor type typically unresponsive to immune checkpoint therapy. As anticipated, treatment with NX-1607 led to increased peripheral T cell activation and proliferation, indicating active T-cell receptor engagement and immune responsiveness, suggesting its potential as an active immune-oncology agent with a unique mechanism distinct from PD-1/PD-L1 therapies.
Advancing Pipeline in Inflammation and Autoimmune Diseases
•Introduced new tablet formulation of bexobrutideg into Phase 1 testing to support an IND for inflammation and autoimmune indications. In 2025, Nurix initiated a Phase 1 single ascending and multiple ascending dose (SAD/MAD) study to evaluate pharmacokinetics
2
(PK), pharmacodynamics (PD), and safety of a new tablet formulation of bexobrutideg. This study is intended to support an IND filing and enable expansion into inflammatory and autoimmune indications beginning in 2026.
•Partner Gilead initiated Phase 1 testing of IRAK-4 degrader. In April 2025, Nurix announced that the FDA cleared the Investigational New Drug (IND) application for GS-6791 (previously NX-0479), a novel, potentially best-in-class oral degrader of IRAK4 being developed in collaboration with Gilead Sciences. GS-6791 is designed to selectively degrade IRAK4, a key signaling protein that drives inflammation in autoimmune and inflammatory diseases. Gilead subsequently initiated an ongoing Phase 1 trial in healthy volunteers, the results of which will inform Nurix’s option for a 50/50 co-development and U.S. profit share.
•Partner Sanofi advanced STAT6 degrader program into IND enabling studies: In June 2025, Nurix announced that Sanofi exercised its option to extend its license for Nurix’s STAT6 program, including the development candidate NX-3911. NX-3911 is an oral, highly selective degrader of STAT6, a key transcription factor within the IL-4/IL-13 signaling pathways that drive inflammation in allergic and type 2 inflammatory conditions, which currently is in IND enabling studies. Sanofi is responsible for all development activities, and Nurix retains an option for a 50/50 U.S. profit share and co-promotion after initial clinical proof of concept.
Corporate and Leadership
•Strengthened financial position to support execution of bexobrutideg pivotal program and expansion into inflammation and autoimmune disease. In October 2025, Nurix closed an underwritten registered offering of 24,485,799 shares of its common stock, providing gross proceeds to Nurix of $250.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix. In addition, Nurix earned $47.0 million in non-dilutive capital through its strategic collaborations with Gilead, Sanofi and Pfizer. Nurix is well capitalized with pro forma cash/investments of $663.8 million1.
•Strengthened leadership with appointments of chief commercial officer and new board members with deep experience in drug development and commercialization. In 2025, Nurix announced the hiring of John Northcott as chief commercial officer, bringing extensive U.S. and global commercial leadership experience, including both pre-launch planning and on-market commercialization in hematology, oncology and a wide range of other therapeutic areas. In addition Nurix also appointed two board members: Roy Baynes, MB.Bch., M.Med., Ph.D., who has extensive experience in the development of innovative, blockbuster medicines during a distinguished career in hematology and oncology, and Roger Dansey, M.D., senior leader in drug development and operations with over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets.
2026 Outlook: Executing the Next Phase of Growth
•Execute pivotal development pathway in CLL:
•Enrollment of pivotal Phase 2 trial – DAYBreak CLL-201
•Initiation of a confirmatory Phase 3 study in patients with r/r CLL in the 2L+ setting comparing bexobrutideg monotherapy to pirtobrutinib - DAYBreak CLL-306
•Initiation of a Phase 1b/2 clinical study in patients with CLL in combination with other therapeutic agents including venetoclax (BCL-2 inhibitor)
3
•Advance Degrader Programs in I&I:
•Bexobrutideg – data from new tablet formulation SAD/MAD study supporting IND in I&I
•GS-6791 IRAK4 degrader – potential Phase 1 results2
•NX-3911 STAT6 degrader – potential IND filing by Sanofi2
•Report Ongoing Clinical Data Updates:
•Bexobrutideg Phase 1a/b CLL cohorts
•Bexobrutideg Phase 1a/b NHL cohorts
•Zelebrudomide Phase 1a cohorts
•Progress Research and Development Pipeline:
•Leverage DEL-AITM platform to fuel wholly owned and partnered drug discovery programs
•Earn additional research milestones and potential licensing fees from its collaborations with Gilead, Sanofi, and Pfizer
1Represents cash balance as of August 31, 2025, plus the net proceeds from the October 2025 registered direct offering
2Statements include Nurix estimate for partnered programs using industry standard timelines based on current stage of development (not official guidance of partners).
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of BTK currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. Bexobrutideg also continues to be studied in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed or refractory B cell malignancies.
About NX-1607
NX-1607 is an investigational first-in-class oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) being developed for immuno-oncology indications, including a range of solid tumor types. CBL-B is a cytoplasmic E3 ubiquitin ligase that negatively regulates T cell activation, making it an attractive target for immuno-oncology and offering a novel therapeutic approach to treat solid tumors. Inhibition of CBL-B in preclinical studies reverses T cell exhaustion, alleviates tumor induced immunosuppression, and may also exert direct antitumor effects. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. Additional information on the NX-1607 clinical trial can be accessed at www.clinicaltrials.gov (NCT05107674).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of
4
multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, and a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s future plans, prospects and strategies, including its plans for the development of bexobrutideg, zelebrudomide and NX-1607; Nurix’s plans to expand bexobrutideg into autoimmune and inflammatory indications; the tolerability, safety profile, therapeutic potential and other advantages of Nurix’s drug candidates; the planned timing and conduct of the clinical trials for Nurix’s drug candidates; the planned timing for the provision of updates and findings from Nurix’s clinical studies; Nurix’s plans and expectations for its collaborations and partnered programs; the potential benefits of Nurix’s collaborations, including potential milestone and sales-related payments; and the potential advantages of Nurix’s DEL-AI platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the risks inherent in the drug development process, including the unexpected emergence of adverse events or other undesirable side effects during clinical development; (ii) uncertainties related to the timing and results of clinical trials; (iii) whether Nurix will be able to fund its research and development activities and achieve its research and development goals; (iv) uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; (v) the impact of economic and market conditions and global and regional events on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (vi) whether Nurix will be able to protect intellectual property and (vii) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the
5
fiscal period ended August 31, 2025, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
Sylvia Wheeler
Wheelhouse Life Science Advisors
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
- ### -
6